Search research articles
Contact Us
Filters
Showing results (31-40 of 116) with videos related to
Page
of 12
Sort By:
Journal of Hepato-Biliary-Pancreatic Sciences
|
January 7, 2022
Impact of microscopic incomplete resection for colorectal liver metastases on surgical margin recurrence: R1-Contact vs R1 < 1 mm margin width
Fabio Ausania, Filippo Landi, Aleix Martínez-Pérez, et al.
Endocrine-Related Cancer
|
December 26, 2008
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer
Rosa Gallego, Jordi Codony-Servat, Xabier García-Albéniz, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
June 18, 2011
Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening
Sandra Pérez-Torras, Anna Vidal-Pla, Rosa Miquel, et al.
Investigational New Drugs
|
October 17, 2008
Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients
Lisardo Ugidos, Salvadora Delgado, Carlos Conill, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
November 25, 2010
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab
Xabier Garcia-Albeniz, Carles Pericay, Virginia Alonso-Espinaco, et al.
Cancer
|
September 1, 2005
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas
Xavier Garcia del Muro, Antonio Lopez-Pousa, Javier Martin, et al.
Medical Oncology (Northwood, London, England)
|
January 23, 2013
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer
Jordi Codony-Servat, Xabier Garcia-Albeniz, Carles Pericay, et al.
Pharmaceuticals (Basel, Switzerland)
|
March 28, 2026
Genetic Variants Associated with Fluoropyrimidine-Induced Toxicity in Real-World Patients After Pre-Emptive <i>DPYD</i> Pharmacogenetic Testing
María Rodríguez-García, Sara Salvador-Martín, Mariam Stephanie Rojas Piedra, et al.
Plos One
|
January 14, 2014
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study
Jorge Aparicio, Carmen García-Mora, Marta Martín, et al.
Reviews on Recent Clinical Trials
|
January 19, 2011
Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Gemma Carrera, Xabier Garcia-Albeniz, Juan Ramón Ayuso, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 116) with videos related to
Sort By:
Page
of 12
Journal of Hepato-Biliary-Pancreatic Sciences
|
January 7, 2022
Impact of microscopic incomplete resection for colorectal liver metastases on surgical margin recurrence: R1-Contact vs R1 < 1 mm margin width
Fabio Ausania, Filippo Landi, Aleix Martínez-Pérez, et al.
Endocrine-Related Cancer
|
December 26, 2008
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer
Rosa Gallego, Jordi Codony-Servat, Xabier García-Albéniz, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
June 18, 2011
Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening
Sandra Pérez-Torras, Anna Vidal-Pla, Rosa Miquel, et al.
Investigational New Drugs
|
October 17, 2008
Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients
Lisardo Ugidos, Salvadora Delgado, Carlos Conill, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
November 25, 2010
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab
Xabier Garcia-Albeniz, Carles Pericay, Virginia Alonso-Espinaco, et al.
Cancer
|
September 1, 2005
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas
Xavier Garcia del Muro, Antonio Lopez-Pousa, Javier Martin, et al.
Medical Oncology (Northwood, London, England)
|
January 23, 2013
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer
Jordi Codony-Servat, Xabier Garcia-Albeniz, Carles Pericay, et al.
Pharmaceuticals (Basel, Switzerland)
|
March 28, 2026
Genetic Variants Associated with Fluoropyrimidine-Induced Toxicity in Real-World Patients After Pre-Emptive <i>DPYD</i> Pharmacogenetic Testing
María Rodríguez-García, Sara Salvador-Martín, Mariam Stephanie Rojas Piedra, et al.
Plos One
|
January 14, 2014
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study
Jorge Aparicio, Carmen García-Mora, Marta Martín, et al.
Reviews on Recent Clinical Trials
|
January 19, 2011
Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Gemma Carrera, Xabier Garcia-Albeniz, Juan Ramón Ayuso, et al.
Page
of 12